Speaker Profile

M.D., Ph.D., VP Scientific & Medical Affairs, Molecular Health GmbH

Biography
Dr Armin Schneider has 20 years track record in leading roles in Biotech drug discovery and development and MD PhD from the University of Heidelberg, Germany. At Molecular Health, Armin pioneers the utilization of the company’s technology, Dataome® – a mighty clinical-molecular knowledge base of drugs, diseases and outcomes into machine learning applications and predictive algorithms to predict drug outcomes and R&D efficiency. He has authored over 150 publications and owns numerous patent families and has a strong background in neurology, pharmacology, molecular biology, and statistics, and specific interest in questions of applying advanced statistical methodology to drug development.


 Session Abstract – PMWC Silicon Valley


Artificial intelligence holds the promise to revolutionize health care and directly impact the clinical trials process via expediting the recruitment of eligible clinical trial patients. The systems currently developed with the use of AI/ML enable higher patient enrollment rates and better trial assignment, contribute to reducing the cost of recruitment via additional/more efficient medical tests, and facilitate analysis and integration of operational data from historical cases. This session focuses on various applications of AI in clinical trial design and patient selection.